Subject to change
Preliminary Program Flyer 2010 (1 MB)
Thursday, June 17, 2010 |
|||
Main Auditorium |
|||
| 06:30 - 07:45 | Satellite Symposium | Presented by: Biolacidem-Biosensors Thierry Lefevre |
|
| 08:00 - 08:05 | Introduction, Objectives & Welcome | Jean-François Tanguay Serge Doucet |
|
| 08:05 - 08:10 | CAIC-ACCI Presidential Address | Erick Schampaert | |
| 08:10 - 08:30 | Review of Hot Cases from 2009 | Robert Welsh Donald Palisaitis Serge Doucet |
|
| 08:30 - 09:00 | What's New in the Management of Acute Coronary Syndrome? |
James Terry Ferguson | |
| 09:00 - 10:00 | LIVE CASES | Royal Jubilee Hospital & Montreal Heart Institute |
|
| 10:00 - 10:30 | Coffee Break | ||
| 10:30 - 11:00 | Cinical Update on Vulnerable Plaque and Patients | Gregg W. Stone | |
| 11:00 - 12:00 | LIVE CASES | Royal Jubilee Hospital & Montreal Heart Institute |
|
| 12:00 - 13:00 | Lunch Break | ||
| 13:00 - 14:00 | Academic and Industry Buzz | ||
| 14:00 - 15:00 | LIVE CASES | Royal Jubilee Hospital & Montreal Heart Institute |
|
| 15:00 - 15:30 | Coffee Break | ||
Small Auditorium Topic: An Hour Focussed on Bifurcation Lesion |
|||
| 15:30 - 15:45 | Debate on crush stenting: pro | Vladimir Dzavik | |
| 15:45 - 16:00 | Debate on crush stenting: con | Thierry Lefevre | |
| 16:00 - 16:15 | Rebutals | Dzavik/Lefevre | |
| 16:15 - 16:30 | Case Review | ||
Main Auditorium |
|||
| 15:30 - 15:45 | The STEMI Patient : Should We Give GP IIb/IIIa Inhibitor and Transfer? | Gilles Montalescot | |
| 15:45 - 16:00 | The STEMI Patient: Should We Give Lysis and Transfer? | Warren Cantor | |
| 16:00 - 16:15 | How to manage the diabetic patient? | Marco Roffi | |
| 16:15 - 16:30 | Patent Foramen Ovale Closure: The Evidence and the Controversy | Mike Mullen | |
| 16:30 - 17:30 | Fellows Cine Reviews- Best Cases in 2009 | Peter Seidelin Reda Ibrahim Stéphane Rinfret Anthony Della Siega |
|
| 17:45 - 19:45 | Satellite Symposium | Presented by: CAIC and supported by AstraZeneca - Medtronic Laura Mauri Eric Cohen Robert Welsh Michael Love Erick Schampaert |
|
Friday, June 18, 2010 |
|||
Main Auditorium |
|||
| 06:30 - 07:45 | Satellite Symposium | Presented by: Boston Scientific Gregg W. Stone |
|
| 08:00 - 08:30 | Core Curriculum: The Chronic Total Occlusion Patient | Bradley Strauss | |
| 08:30 - 08:45 | How to Approach the Patient with Vein Graft Disease? | Josép Rodes-Cabau | |
| 08:45 - 09:00 | How to Approach a Patient with a Bifurcation Lesion? | Thierry Lefevre | |
| 09:00 - 10:00 | LIVE CASES | Duke University Medical Center & Montreal Heart Institute |
|
| 10:00 - 10:30 | Coffee Break | ||
| 10:30 - 10:45 | Update on Antiplatelet Therapy | Stephen Wiviott | |
| 10:45 - 11:00 | Timing of Revascularisation and Risk Assessment in ACS |
Shamir R. Mehta | |
| 11:00 - 12:00 | LIVE CASES | Duke University Medical Center & Montreal Heart Institute |
|
| 12:00 - 13:00 | Lunch Break | ||
| 13:00 - 14:00 | Academic and Industry Buzz | ||
| 14:00 - 15:00 | LIVE CASES | Duke University Medical Center & Montreal Heart Institute |
|
| 15:00 - 15:30 | Coffee Break | ||
Small Auditorium Topic: An Hour Focussed on CTO |
|||
| 15:30 - 15:45 | The histopathology of the CTO | Bradley Strauss | |
| 15:45 - 16:00 | Why should we open CTO? | Christopher Buller | |
| 16:00 - 16:15 | New techniques in CTO recanalization | Stéphane Rinfret | |
| 16:15 - 16:30 | Case Review | ||
Main Auditorium |
|||
| 15:30 - 15:45 | Update on Medical Management of CAD | E. Magnus Ohman | |
| 15:45 - 16:00 | Percutaneous Valvular Interventions | Nicolo Piazza | |
| 16:00 - 16:15 | Update and Future of Stem Cell Therapy | Tim Henry | |
| 16:15 - 16:30 | What's New in Prevention or Treatment of Restenosis? | Flavio Ribichini | |
| 16:30 - 17:30 | Fellows Cine Reviews Worst Nightmares in 2009 |
Peter Seidelin Reda Ibrahim Stéphane Rinfret Anthony Della Siega |
|
| 17:45 - 19:00 | Satellite Symposium | Presented by: Abbott Vascular Richard Rapoza Charles Simonton |
|
Saturday, June 19, 2010 |
|||
| 08:00 - 08:15 | Opening Remarks In honor of the pioneers in cardiac MR in Montréal; Eleonore Paquet and Renée Déry |
Josephine Pressacco | |
Atherosclerosis - Moderator W. Willinek Expert Panel - James K. Min / Josephine Pressacco / Jean-Claude Tardif |
|||
| 08:15 - 08:45 | The Role of Imaging Biomarkers in Atherosclerosis | Jean-Claude Tardif | |
| 08:45 - 08:55 | Question Period | ||
| 08:55 - 09:25 | MR Evaluation of Atherosclerosis | David Maintz | |
| 09:25 - 09:35 | Question Period | ||
| 09:35 - 10:05 | MRI of Endorgan Damage in Atherosclerosis | Christopher M. Kramer | |
| 10:05 - 10:15 | Question Period | ||
| 10:15 - 10:45 | Coffee Break | ||
| 10:45 - 11:15 | Appropriateness Criteria for Imaging in Revascularisation | Manesh R. Patel | |
| 11:15 - 11:25 | Question Period | ||
Case Session - Moderator: Winfried A. Willinek Expert Panel - James K. Min / David Maintz / Yves Provost |
|||
| 11:25 - 11:50 | Interesting MR Cases | François Marcotte | |
| 11:50 - 12:00 | Question Period | ||
| 12:00 - 13:00 | Lunch Break | ||
DEBATE - CT versus MRI for CAD – Moderator: Anita Asgar Expert Panel - Raymond Y. Kwong |
|||
| 13:00 - 13:15 | CT is the Modality of Choice for Coronary Artery Imaging | James K. Min | |
| 13:15 - 13:30 | MR is the Modality of Choice for Coronary Artery Imaging | Matthias G. Friedrich | |
| 13:30 - 13:45 | Rebuttal | James K. Min Matthias G. Friedrich |
|
Heart Failure - Moderator: Matthias G. Friedrich Expert Panel – Normand Racine |
|||
| 13:45 - 14:15 | Heart Failure: A story of Causes and Consequences | J. Malcolm O. Arnold | |
| 14:15 - 14:25 | Question Period | ||
| 14:25 - 14:55 | MR Evaluation of Heart Failure | Winfried A. Willinek | |
| 14:55 - 15:05 | Question Period | ||
| 15:05 - 15:35 | Myocardial Late Enhancement: Description, Applications and Current Update |
Raymond Y. Kwong | |
| 15:35 - 15:45 | Question Period | ||
Closing Remarks - Anita Asgar |
|||
DisclosureSymposium speakers sign a disclosure statement to confirm any interest or affiliation with one or more organizations that could be perceived as a conflict of interest. Additionally, the “off-label” or investigational use of medical devices or pharmaceutical products must be announced to the audience during presentation. |
|||
